Do COVID-19 mRNA vaccines result in antibody production in MPN patients, particularly those on treatment? Data from 74 patients from the MSK Leukemia service (@MartinTallman ) published today:
rdcu.be/cAQ82 #mpnsm
rdcu.be/cAQ82 #mpnsm
We studied 22CML, 14ET, 14PV, 22MF and 2 MPN-BP patients, (on treatment or on observation).
71 of 74 patients became seropositive after 2 doses of Pfizer or Moderna vaccine.
71 of 74 patients became seropositive after 2 doses of Pfizer or Moderna vaccine.
2 patients on ruxolitinib and 1 patient on ponatinib did not respond to vaccine. A trend toward lower antibody levels noted in ruxolitinib treated patients was observed. A trend toward higher antibody levels noted in some interferon treated patients.
Antibody levels declined over time by a mean of 67% in a subgroup of patients. However 3rd dose (booster) resulted in an increase in antibody levels by 200%.
What this means for protection against infection/mortality not evaluated in our data. We also did not study T cell aspects of immunity (@joanhowMD and @GabyHobbs will present insights on this topic at ASH, per abstracts released yesterday)
Finally, this work was lead by our clinic RN and NP (Kathryn Kozak and Linda Ouyang) with key contributions from PharmD Ryan Daley (all of whom don't exist in twitter universe). True multidisciplinary effort.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
